Lawsuits Allege Actos® Drug Linked to Increased Bladder Cancer Risk

Share Article

Climaco, Wilcox, Peca, Tarantino & Garofoli Co., L.P.A. has filed several lawsuits against the manufacturer of Actos®. Actos® is a prescription medication used to treat type II diabetes. The FDA recently issued a safety alert to the public indicating that the use of Actos® for more than one year may increase the risk of developing bladder cancer.

Climaco, Wilcox, Peca, Tarantino & Garofoli Co., L.P.A. has filed several lawsuits against Takeda Pharmaceuticals, the manufacturer of the diabetes medication Actos® (pioglitazone), in the United States District Court for the Northern District of Ohio, Eastern Division. The initial Climaco lawsuit was among the first filed Actos® actions and arises from claims by an Ohio resident who developed bladder cancer after taking Actos® for about one year. The case number is 1:11-cv-01565 (Northern District of Ohio, Eastern Division). The Complaint was filed on July 29, 2011. In the Complaint, Plaintiff alleges that Takeda failed to warn of the risks of bladder cancer and if Plaintiff had been warned of the dangers connected with the drug, Plaintiff would not have taken Actos®. The Plaintiff is seeking monetary damages from Takeda for injuries.

The Federal Food and Drug Administration issued a safety alert to the public on June 15, 2011 relating to the use of Actos®. The FDA recommended that 1) Actos® not be taken by individuals with bladder cancer; 2) Actos® should be used with caution in patients with a history of bladder cancer; and 3) Actos® should not be stopped without a doctor’s advice, since the benefit of glycemic control needs to be weighed against the risk of cancer in each individual. The FDA is also requiring a new safety label that will indicate that “the use of Actos for more than one year may increase a person’s chance of bladder cancer.” Actos® sales were suspended in France and Germany in June, 2011, due to the bladder cancer concerns. Shortly thereafter in the United States, an FDA interim review board cautioned that patients taking Actos® for over a year may have an increased risk of bladder cancer. The FDA review is ongoing and thus far, Actos® has not been removed from the U.S. market. The FDA safety alert can be accessed by clicking here: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226257.htm

About John R. Climaco

John R. Climaco, founder and chairman at Climaco, Wilcox, Peca, Tarantino & Garofoli Co., L.P.A. in Cleveland, Ohio has successfully led some of the largest class actions in U.S. history. John devotes his comprehensive practice to General and Complex Litigation, including Class Actions, Securities, ERISA, Mass Torts, Environmental, Toxic Tort, White Collar Criminal and Civil RICO, and Public Law matters. The National Law Journal named John one of the one hundred most powerful lawyers in the United States. John is a member of the Castano Plaintiffs Legal Committee which in 1999 filed the first nicotine addiction action against the tobacco industry. Castano, along with Mississippi, Texas and Florida are recognized as Tobacco Pioneers. The Pioneer’s efforts resulted in the $1.250 Billion Dollar settlement with the tobacco industry. Also, he was part of the leadership team that reached a settlement for 443 injured claimants in the In re: Oral Sodium Phosphate Solution-Based Products Liability Action, Case No. 1:09-sp-80000, (MDL Docket No. 2066), United States District Court, Northern District Of Ohio, Eastern Division.

About Climaco, Wilcox, Peca, Tarantino & Garofoli Co., L.P.A.

Climaco, Wilcox, Peca, Tarantino & Garofoli Co., L.P.A. is a full-service law firm that has provided superior legal services to its clients since 1969. Climaco, Wilcox, Peca, Tarantino & Garofoli Co., L.P.A. has positioned itself as a highly regarded firm of local and national prominence by blending expert legal skills with common sense, client commitment and loyalty. The firm has practice groups in Class Actions, Litigation, Business Law, Employment Law and Government and Public Finance. The firm is committed to each of its clients and to the community. For more information please visit: http://www.climacolaw.com or http://www.injuredbyactos.com.

# # #

Share article on social media or email:

View article via:

Pdf Print